Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.
- DOI
- 10.3389/fonc.2022.929763
- Published
- 2022
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2022.929763,
title = {Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.},
author = {Wang SS and Wang F and Zeng Z and Gao F and Liu HH and Wang HN and Hu Y and Qin HF},
year = {2022},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2022.929763},
url = {https://doi.org/10.3389/fonc.2022.929763}
}RIS
TY - JOUR TI - Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient. AU - Wang SS AU - Wang F AU - Zeng Z AU - Gao F AU - Liu HH AU - Wang HN AU - Hu Y AU - Qin HF PY - 2022 JO - Frontiers in oncology DO - 10.3389/fonc.2022.929763 UR - https://doi.org/10.3389/fonc.2022.929763 ER -
APA
SS, W., F, W., Z, Z., F, G., HH, L., HN, W., Y, H., & HF, Q. (2022). Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.929763
Source records
- pubmed · retrieved 2026-09-25T22:39:37.103Z